|
Executive Drive OncoSec Medical Inc. 4690 Executive Drive Suite 250 San Diego California, 92121 855.662.6732 |
 |
OncoSec‘s New Patent For OMS Electroporation Device Approved By China
Online PR News – 06-September-2012 –SAN DIEGO – September 5, 2012 – OncoSec Medical Inc. (OTCBB: ONCS), a company
developing its advanced-stage ImmunoPulse and NeoPulse technologies to treat
solid tumor cancers, received a new Method of Use and Device patent (Patent
Application No. 200780014313.0, “Method and Device for Treating Microscopic
Residual Tumors Remaining in Tissues Following Surgical Resection”) for the
OncoSec Medical System (OMS) electroporation device platform from the State
Intellectual Property Office of the People’s Republic of China. The issuance
of this patent has the potential to expand OncoSec’s commercial opportunities
for minimally invasive and surgical procedures to treat solid tumors in a very
large market such as China.
Punit Dhillon, OncoSec’s President and CEO, commented, “The issuance of this
patent is significant, because the Chinese authorities have given the company
patent approval for our claims regarding the OMS electroporation device
itself, as well as the method of use. These are broad claims, wherein OncoSec
now has the ability to deliver various therapeutic agents through its
electroporation device, including bleomycin and DNA IL-12, as well as to treat
tumors with these agents following surgical resection. Thus, this patent will
act as a part of the company’s core strategy as we continue to develop and
build our commercialization strategy in China, one of the largest emerging
oncology markets.”
Numerous research studies have concluded that cancer has now become a leading
cause of mortality in China, representing 25 percent of all deaths in urban
areas and 21 percent in rural areas. Moreover, cancer mortality in China has
been increasing rapidly and continuously during the past three decades, which
indicates a significant need for novel therapies.
ImmunoPulse and NeoPulse are investigational therapies being evaluated to
reduce the rate of cancer recurrence while minimizing quality-of-life side
effects. These therapeutic approaches, as potential adjuncts to surgery,
involve injecting the tumor with an anti-cancer agent, followed by
electroporation to open up the cell membrane, which helps significantly
increase the uptake of the agent. This approach has been shown to selectively
kill cancer cells that may exist in the neighboring tissue, which may result
in a reduced rate of recurrence and has the potential to complement standard-
of-care surgical procedures.
| Bookmarks |  |  |  |  |  |  |  |  |  |  |  |  |  |
